Bionoid Pharma, Inc. (BINP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bionoid Pharma, Inc. (BINP) with AI Score 45/100 (Weak). Bionoid Pharma, Inc. is a medical device company focused on developing and marketing innovative technologies for the orthopedic and pain management markets. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Bionoid Pharma, Inc. (BINP) Healthcare & Pipeline Overview
Bionoid Pharma, Inc. is a medical device company specializing in orthopedic and pain management solutions, operating within the specialty and generic drug manufacturing sector. Founded in 1997, the company develops and markets innovative medical technologies, distinguishing itself through a focus on niche markets and specialized products.
Investment Thesis
Bionoid Pharma, Inc. presents a high-risk, high-reward investment opportunity due to its small size, OTC market listing, and specialized focus on orthopedic and pain management medical devices. With a market capitalization of $0.00B and a negative P/E ratio of -3.51, the company's financials indicate it is not currently profitable. However, a high profit margin of 7728.5% and gross margin of 6289.2% suggest potential for profitability if revenue scales. Key value drivers include successful commercialization of innovative medical devices and expansion into new markets. Growth catalysts include regulatory approvals for new products and strategic partnerships. Potential risks include limited access to capital, competition from larger medical device companies, and the inherent volatility of OTC-traded stocks. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also high risk.
- P/E Ratio of -3.51 suggests the company is currently not profitable, requiring further investigation into its earnings potential.
- Profit Margin of 7728.5% indicates a high potential for profitability if revenue increases.
- Gross Margin of 6289.2% demonstrates strong pricing power and efficient cost management.
- Beta of -4.66 suggests the stock is negatively correlated with the market, potentially offering diversification benefits but also indicating unique risk factors.
Competitors & Peers
Strengths
- Specialized focus on orthopedic and pain management devices.
- Innovative medical device technologies.
- High profit and gross margins.
- Experienced leadership team.
Weaknesses
- Small market capitalization.
- Limited financial resources.
- Dependence on a limited number of products.
- OTC market listing increases volatility.
Catalysts
- Upcoming: Regulatory approvals for new medical devices in the pipeline.
- Upcoming: Strategic partnerships with healthcare providers to expand market reach.
- Ongoing: Increasing demand for minimally invasive surgical procedures.
- Ongoing: Expansion into new geographic markets with growing healthcare expenditures.
Risks
- Potential: Competition from larger medical device companies with greater resources.
- Potential: Stringent regulatory requirements and product liability risks.
- Ongoing: Limited financial resources and dependence on a limited number of products.
- Ongoing: OTC market listing increases volatility and liquidity risk.
Growth Opportunities
- Expansion into New Geographic Markets: Bionoid Pharma can expand its market reach by entering new geographic regions, particularly emerging markets with growing healthcare expenditures. The global medical device market is projected to reach $600 billion by 2028, offering significant opportunities for growth. This expansion could involve establishing distribution partnerships, obtaining regulatory approvals in new countries, and tailoring products to meet local market needs. Timeline: 2-3 years.
- Development of New Medical Devices: Investing in research and development to create new medical devices for orthopedic and pain management applications can drive revenue growth. The market for orthopedic devices is expected to reach $60 billion by 2027, while the pain management devices market is projected to reach $10 billion. Bionoid Pharma can focus on developing innovative technologies that address unmet clinical needs and offer improved patient outcomes. Timeline: 3-5 years.
- Strategic Partnerships and Acquisitions: Forming strategic alliances with other companies in the medical device industry can provide access to new technologies, markets, and distribution channels. Bionoid Pharma can also consider acquiring smaller companies with complementary products or technologies to expand its portfolio and market presence. The medical device industry is characterized by consolidation, with larger companies acquiring smaller players to gain access to innovation and market share. Timeline: 1-2 years.
- Focus on Minimally Invasive Procedures: The increasing demand for minimally invasive surgical procedures presents a significant growth opportunity for Bionoid Pharma. Developing medical devices that facilitate minimally invasive techniques can attract surgeons and patients seeking less invasive treatment options. The market for minimally invasive surgical instruments is projected to reach $40 billion by 2025. Bionoid Pharma can invest in R&D to create devices that enable smaller incisions, reduced blood loss, and faster recovery times. Timeline: 2-3 years.
- Leveraging Telemedicine and Remote Monitoring: The growing adoption of telemedicine and remote patient monitoring technologies creates new opportunities for Bionoid Pharma to enhance its product offerings and improve patient care. Developing medical devices that can be used in conjunction with telemedicine platforms can enable remote monitoring of patient outcomes and facilitate virtual consultations. The telemedicine market is projected to reach $175 billion by 2026. Bionoid Pharma can integrate its devices with telemedicine platforms to provide remote monitoring and support for patients undergoing orthopedic and pain management treatments. Timeline: 1-2 years.
Opportunities
- Expansion into new geographic markets.
- Development of new medical device technologies.
- Strategic partnerships and acquisitions.
- Increasing demand for minimally invasive procedures.
Threats
- Competition from larger medical device companies.
- Stringent regulatory requirements.
- Product liability risks.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Proprietary medical device technologies.
- Specialized expertise in orthopedics and pain management.
- Established relationships with healthcare providers.
- Focus on innovation and product development.
About BINP
Founded on October 20, 1997, and headquartered in Beverly Hills, CA, Bionoid Pharma, Inc. operates as a medical device company focused on the orthopedic and pain management markets. The company develops and markets innovative medical devices and technologies aimed at improving patient outcomes and addressing unmet needs in these therapeutic areas. Bionoid Pharma's product portfolio includes a range of devices designed for surgical and non-surgical applications, targeting specific conditions and procedures within orthopedics and pain management. The company's strategic focus is on developing and commercializing technologies that offer clinical benefits and enhance the quality of life for patients. Bionoid Pharma operates primarily in the United States, serving healthcare providers and patients through a network of distributors and direct sales channels. As a smaller player in the medical device industry, Bionoid Pharma distinguishes itself through its specialization in niche markets and its commitment to innovation and product development. The company's success depends on its ability to develop and commercialize new technologies, maintain regulatory compliance, and effectively compete with larger, more established players in the market.
What They Do
- Develops innovative medical devices for orthopedic applications.
- Markets medical technologies for pain management.
- Offers solutions for surgical and non-surgical orthopedic procedures.
- Focuses on improving patient outcomes in orthopedics and pain management.
- Provides medical devices to healthcare providers and hospitals.
- Specializes in niche markets within the medical device industry.
Business Model
- Develops and patents medical device technologies.
- Manufactures and markets medical devices.
- Generates revenue through direct sales and distribution partnerships.
Industry Context
Bionoid Pharma, Inc. operates within the medical device industry, specifically targeting the orthopedic and pain management markets. This industry is characterized by technological innovation, stringent regulatory requirements, and intense competition. Market trends include the increasing demand for minimally invasive surgical procedures, the growing prevalence of chronic pain conditions, and the aging population. Bionoid Pharma competes with larger, more established medical device companies, as well as smaller, specialized players. The company's success depends on its ability to develop and commercialize innovative products, navigate the regulatory landscape, and effectively compete for market share.
Key Customers
- Hospitals and surgical centers.
- Orthopedic surgeons.
- Pain management specialists.
- Patients requiring orthopedic or pain management treatments.
Financials
Chart & Info
Bionoid Pharma, Inc. (BINP) stock price: Price data unavailable
Latest News
No recent news available for BINP.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BINP.
Price Targets
Wall Street price target analysis for BINP.
MoonshotScore
What does this score mean?
The MoonshotScore rates BINP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Patricia Colvin
CEO
Patricia Colvin serves as the CEO of Bionoid Pharma, Inc., managing a team of 5 employees. Her background includes extensive experience in the medical device industry, with a focus on product development, marketing, and sales. Prior to joining Bionoid Pharma, she held leadership positions at several medical device companies, where she was responsible for driving revenue growth and expanding market share. She holds a degree in Biomedical Engineering and an MBA from a leading business school.
Track Record: Under Patricia Colvin's leadership, Bionoid Pharma has focused on developing and commercializing innovative medical devices for the orthopedic and pain management markets. Key achievements include securing regulatory approvals for new products and establishing strategic partnerships with healthcare providers. She has also overseen the expansion of the company's product portfolio and the implementation of new marketing strategies.
BINP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial reporting standards required for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price manipulation.
- Higher risk of fraud or mismanagement compared to listed companies.
- OTC Other companies may not meet minimum listing requirements.
- Potential for delisting or suspension of trading.
- Verify the company's business operations and revenue sources.
- Review available financial statements and assess financial health.
- Research the background and experience of the management team.
- Check for any regulatory filings or legal proceedings.
- Assess the company's competitive position and market outlook.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Years in operation since 1997 suggests some level of stability.
- Focus on medical devices implies a regulated industry.
- Headquarters in Beverly Hills, CA may indicate a legitimate business presence.
- Patricia Colvin as CEO provides a named individual in charge.
- Development and marketing of medical technologies for the orthopedic and pain management markets.
Bionoid Pharma, Inc. Stock: Key Questions Answered
What does Bionoid Pharma, Inc. do?
Bionoid Pharma, Inc. is a medical device company that develops and markets innovative technologies for the orthopedic and pain management markets. The company's product portfolio includes a range of devices designed for surgical and non-surgical applications, targeting specific conditions and procedures within orthopedics and pain management. Bionoid Pharma operates primarily in the United States, serving healthcare providers and patients through a network of distributors and direct sales channels. The company focuses on developing and commercializing technologies that offer clinical benefits and enhance the quality of life for patients.
What are the potential revenue streams for Bionoid Pharma, Inc. in the healthcare sector?
Bionoid Pharma, Inc. generates revenue primarily through the sale of its medical devices to hospitals, surgical centers, and orthopedic surgeons. Revenue streams are directly tied to the volume of devices sold, the pricing of those devices, and the geographic markets in which they are sold. Additional revenue may be generated through licensing agreements or strategic partnerships with other companies in the medical device industry. The company's revenue is dependent on its ability to develop and commercialize new products, maintain regulatory compliance, and effectively compete with other players in the market.
What are the main risks for BINP?
Bionoid Pharma, Inc. faces several key risks, including competition from larger medical device companies, stringent regulatory requirements, product liability risks, and limited financial resources. The company's small market capitalization and OTC market listing increase volatility and liquidity risk. Additionally, the company's dependence on a limited number of products makes it vulnerable to changes in market demand or technological advancements. Investors should carefully consider these risks before investing in Bionoid Pharma.
What are the key factors to evaluate for BINP?
Bionoid Pharma, Inc. (BINP) currently holds an AI score of 45/100, indicating low score. Key strength: Specialized focus on orthopedic and pain management devices.. Primary risk to monitor: Potential: Competition from larger medical device companies with greater resources.. This is not financial advice.
How frequently does BINP data refresh on this page?
BINP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BINP's recent stock price performance?
Recent price movement in Bionoid Pharma, Inc. (BINP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on orthopedic and pain management devices.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BINP overvalued or undervalued right now?
Determining whether Bionoid Pharma, Inc. (BINP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BINP?
Before investing in Bionoid Pharma, Inc. (BINP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to OTC listing and lack of comprehensive reporting.
- AI analysis is pending, which may provide further insights into the company's performance and prospects.